BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20004946)

  • 1. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
    Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
    Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
    Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
    Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
    Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
    J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
    Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
    Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
    Krengel S; Grotel├╝schen F; Bartsch S; Tronnier M
    J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
    Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
    Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions.
    Sharma BK; Smith CC; Laing JM; Rucker DA; Burnett JW; Aurelian L
    Dermatology; 2006; 213(3):192-9. PubMed ID: 17033167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
    Clark WH; Hood AF; Tucker MA; Jampel RM
    Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
    Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective look at dysplastic nevi. What were they in 1978 and how have they fared since?
    Cockerell CJ; Berson DS
    Am J Dermatopathol; 1985; 7 Suppl():93-7. PubMed ID: 3940095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
    Clark WH; Elder DE; Guerry D; Epstein MN; Greene MH; Van Horn M
    Hum Pathol; 1984 Dec; 15(12):1147-65. PubMed ID: 6500548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions.
    Stefanou D; Batistatou A; Zioga A; Arkoumani E; Papachristou DJ; Agnantis NJ
    Int J Surg Pathol; 2004 Apr; 12(2):133-8. PubMed ID: 15173918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative activity of primary cutaneous melanocytic tumours.
    Kuwata T; Kitagawa M; Kasuga T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of estrogen receptors in dysplastic nevi and malignant melanoma.
    Lecavalier MA; From L; Gaid N
    J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.